Table 2.
Treatment Efficacy | ||
---|---|---|
Treatment | SUCRA | Rank |
PARPi | 90% | 1 |
BEV | 60% | 2 |
CT | 0% | 3 |
SUCRA: surface under the cumulative ranking value; PARPi: poly (ADP-ribose) polymerase inhibitors; BEV bevacizumab; CT: chemotherapy without maintenance treatment.